New drugs for myelofibrosis

Gabriela Hobbs, Ruben Mesa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Myelofibrosis (MF) is a clonal myeloid neoplasm associated with cytopenias, significant symptom burden and risk of transformation to acute leukemia. Discovery of the JAK2V617F mutation in the majority of patients with myeloproliferative neoplasms led to the development and approval of ruxolitinib, the first JAK1/2 inhibitor for use in clinical practice. Better understanding of the molecular biology of MF has led to the development of a variety of new drugs that are currently undergoing testing for MF.Areas covered: Here we discuss the diagnosis and risk stratification of patients with MF. We review the use of ruxolitinib, ongoing studies in combination with this agent, and examine the spectrum of therapies under investigation for MF.Expert opinion: Ruxolitinib represents an important step in the treatment of MF; it can effectively alleviate symptomatic burden and reduce splenomegaly, unfortunately it does not lead to disease remissions. As a result, several new JAK inhibitors are undergoing advanced clinical testing, notably momelotinib and pacritinib. In addition, several trials are focusing on combinations with these agents. Improved understanding of the disease biology of MF has encouraged the development of new agents with a variety of targets, such as fibrosis, telomerase, PI3K, hedgehog, HSP90 and mTOR inhibition among others.

Original languageEnglish (US)
Pages (from-to)521-529
Number of pages9
JournalExpert Opinion on Orphan Drugs
Volume4
Issue number5
DOIs
StatePublished - May 3 2016

Fingerprint

Primary Myelofibrosis
Pharmaceutical Preparations
Telomerase
Splenomegaly
Expert Testimony
Phosphatidylinositol 3-Kinases
Molecular Biology
Neoplasms
Leukemia
Fibrosis
Mutation
Therapeutics
INCB018424

Keywords

  • JAK inhibitor
  • myelofibrosis
  • Myeloproliferative neoplasm
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

New drugs for myelofibrosis. / Hobbs, Gabriela; Mesa, Ruben.

In: Expert Opinion on Orphan Drugs, Vol. 4, No. 5, 03.05.2016, p. 521-529.

Research output: Contribution to journalArticle

Hobbs, Gabriela ; Mesa, Ruben. / New drugs for myelofibrosis. In: Expert Opinion on Orphan Drugs. 2016 ; Vol. 4, No. 5. pp. 521-529.
@article{dae43782a73240da9a2278a875320ae4,
title = "New drugs for myelofibrosis",
abstract = "Introduction: Myelofibrosis (MF) is a clonal myeloid neoplasm associated with cytopenias, significant symptom burden and risk of transformation to acute leukemia. Discovery of the JAK2V617F mutation in the majority of patients with myeloproliferative neoplasms led to the development and approval of ruxolitinib, the first JAK1/2 inhibitor for use in clinical practice. Better understanding of the molecular biology of MF has led to the development of a variety of new drugs that are currently undergoing testing for MF.Areas covered: Here we discuss the diagnosis and risk stratification of patients with MF. We review the use of ruxolitinib, ongoing studies in combination with this agent, and examine the spectrum of therapies under investigation for MF.Expert opinion: Ruxolitinib represents an important step in the treatment of MF; it can effectively alleviate symptomatic burden and reduce splenomegaly, unfortunately it does not lead to disease remissions. As a result, several new JAK inhibitors are undergoing advanced clinical testing, notably momelotinib and pacritinib. In addition, several trials are focusing on combinations with these agents. Improved understanding of the disease biology of MF has encouraged the development of new agents with a variety of targets, such as fibrosis, telomerase, PI3K, hedgehog, HSP90 and mTOR inhibition among others.",
keywords = "JAK inhibitor, myelofibrosis, Myeloproliferative neoplasm, targeted therapy",
author = "Gabriela Hobbs and Ruben Mesa",
year = "2016",
month = "5",
day = "3",
doi = "10.1517/21678707.2016.1171141",
language = "English (US)",
volume = "4",
pages = "521--529",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - New drugs for myelofibrosis

AU - Hobbs, Gabriela

AU - Mesa, Ruben

PY - 2016/5/3

Y1 - 2016/5/3

N2 - Introduction: Myelofibrosis (MF) is a clonal myeloid neoplasm associated with cytopenias, significant symptom burden and risk of transformation to acute leukemia. Discovery of the JAK2V617F mutation in the majority of patients with myeloproliferative neoplasms led to the development and approval of ruxolitinib, the first JAK1/2 inhibitor for use in clinical practice. Better understanding of the molecular biology of MF has led to the development of a variety of new drugs that are currently undergoing testing for MF.Areas covered: Here we discuss the diagnosis and risk stratification of patients with MF. We review the use of ruxolitinib, ongoing studies in combination with this agent, and examine the spectrum of therapies under investigation for MF.Expert opinion: Ruxolitinib represents an important step in the treatment of MF; it can effectively alleviate symptomatic burden and reduce splenomegaly, unfortunately it does not lead to disease remissions. As a result, several new JAK inhibitors are undergoing advanced clinical testing, notably momelotinib and pacritinib. In addition, several trials are focusing on combinations with these agents. Improved understanding of the disease biology of MF has encouraged the development of new agents with a variety of targets, such as fibrosis, telomerase, PI3K, hedgehog, HSP90 and mTOR inhibition among others.

AB - Introduction: Myelofibrosis (MF) is a clonal myeloid neoplasm associated with cytopenias, significant symptom burden and risk of transformation to acute leukemia. Discovery of the JAK2V617F mutation in the majority of patients with myeloproliferative neoplasms led to the development and approval of ruxolitinib, the first JAK1/2 inhibitor for use in clinical practice. Better understanding of the molecular biology of MF has led to the development of a variety of new drugs that are currently undergoing testing for MF.Areas covered: Here we discuss the diagnosis and risk stratification of patients with MF. We review the use of ruxolitinib, ongoing studies in combination with this agent, and examine the spectrum of therapies under investigation for MF.Expert opinion: Ruxolitinib represents an important step in the treatment of MF; it can effectively alleviate symptomatic burden and reduce splenomegaly, unfortunately it does not lead to disease remissions. As a result, several new JAK inhibitors are undergoing advanced clinical testing, notably momelotinib and pacritinib. In addition, several trials are focusing on combinations with these agents. Improved understanding of the disease biology of MF has encouraged the development of new agents with a variety of targets, such as fibrosis, telomerase, PI3K, hedgehog, HSP90 and mTOR inhibition among others.

KW - JAK inhibitor

KW - myelofibrosis

KW - Myeloproliferative neoplasm

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84964088523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964088523&partnerID=8YFLogxK

U2 - 10.1517/21678707.2016.1171141

DO - 10.1517/21678707.2016.1171141

M3 - Article

AN - SCOPUS:84964088523

VL - 4

SP - 521

EP - 529

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 5

ER -